Effects of Three Different Testosterone Formulations in Female‐to‐Male Transsexual Persons

Gender dysphoria is characterized by a strong discomfort with the gender assigned at birth and the urge to live as a member of the opposite gender. The acquisition of phenotypic features of the desired gender requires the use of cross‐sex hormones. Female‐to‐male (FtM) transsexual persons are treate...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of sexual medicine 2014-12, Vol.11 (12), p.3002-3011
Hauptverfasser: Pelusi, Carla, Costantino, Antonietta, Martelli, Valentina, Lambertini, Martina, Bazzocchi, Alberto, Ponti, Federico, Battista, Giuseppe, Venturoli, Stefano, Meriggiola, Maria C.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 3011
container_issue 12
container_start_page 3002
container_title Journal of sexual medicine
container_volume 11
creator Pelusi, Carla
Costantino, Antonietta
Martelli, Valentina
Lambertini, Martina
Bazzocchi, Alberto
Ponti, Federico
Battista, Giuseppe
Venturoli, Stefano
Meriggiola, Maria C.
description Gender dysphoria is characterized by a strong discomfort with the gender assigned at birth and the urge to live as a member of the opposite gender. The acquisition of phenotypic features of the desired gender requires the use of cross‐sex hormones. Female‐to‐male (FtM) transsexual persons are treated with testosterone to induce virilization. The aim of the study was to assess the effects of three different testosterone formulations on body weight and composition and metabolic and bone parameters. Forty‐five FtM transsexuals were randomly assigned to receive testoviron depot (i.m.: 100 mg/10 days; n = 15), testosterone gel (50 mg/die; n = 15), and testosterone undecanoate (i.m.: 1,000 mg every 6 weeks for the first 6 weeks and then every 12 weeks, n = 15). FtM individuals were studied before, at week 30, and at week 54 of testosterone treatment. Anthropometric, metabolic, bone, hematological, and biochemical parameters were evaluated at baseline and after 12 months of treatment. Lean body mass significantly increased and fat mass decreased in all groups. No modifications were reported in fasting insulin and insulin sensitivity index. High‐density plasma lipoprotein levels declined significantly and low‐density lipoprotein concentrations increased significantly in the three groups. The activated partial thromboplastin time and factor I did not change while prothrombin time significantly increased in all groups. At week 54, all subjects were amenorrheic and time to amenorrhea did not differ between the three groups. Current general life satisfaction was increased in all subjects after 1 year of treatment. One‐year testosterone administration in FtM transsexuals appears to be very safe with no differences among the testosterone formulations used. Our study is preliminary, and the detection of subtle or long‐term differences in the effects of the three formulations may require further larger and longer term studies in this and other populations. Pelusi C, Costantino A, Martelli V, Lambertini M, Bazzocchi A, Ponti F, Battista G, Venturoli S, and Meriggiola MC. Effects of three different testosterone formulations in female‐to‐male transsexual persons. J Sex Med 2014;11:3002–3011.
doi_str_mv 10.1111/jsm.12698
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1634285230</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1743609515306263</els_id><sourcerecordid>1634285230</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4358-522e2e8d2d1f21e7c366cde8538aa97abb3dc8e4dcce428eeb065e5a7cff16033</originalsourceid><addsrcrecordid>eNp1kUtOwzAQhi0EoqWw4ALIS1ik9aNO0iUqLQ-1AomyxXKdiXCVxMVOgO44AmfkJBjasoJZjEejb37N_EbomJIuDdFb-LJLWTxId1CbJn0exZQMdrc1GYgWOvB-QQgPwfZRiwkmSJKSNnoc5Tno2mOb49mTA8AXJnQcVDWega-tr8HZCvDYurIpVG1s5bGp8BhKVcDn-0dtQ5qGGs-cqryHt0YV-A6cD-Qh2stV4eFo83bQw3g0G15Fk9vL6-H5JNJ9LtJIMAYM0oxlNGcUEs3jWGeQCp4qNUjUfM4znUI_0xr6LAWYk1iAUInOcxqHszrodK27dPa5CXvL0ngNRaEqsI2XNOZhTjBOAnq2RrWz3jvI5dKZUrmVpER-2ymDnfLHzsCebGSbeQnZL7n1LwC9NfBqClj9ryRv7qdbSb6egGDHiwEnvTZQaciMCx8hM2v-WOQLTdqUNQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1634285230</pqid></control><display><type>article</type><title>Effects of Three Different Testosterone Formulations in Female‐to‐Male Transsexual Persons</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Wiley Online Library All Journals</source><creator>Pelusi, Carla ; Costantino, Antonietta ; Martelli, Valentina ; Lambertini, Martina ; Bazzocchi, Alberto ; Ponti, Federico ; Battista, Giuseppe ; Venturoli, Stefano ; Meriggiola, Maria C.</creator><creatorcontrib>Pelusi, Carla ; Costantino, Antonietta ; Martelli, Valentina ; Lambertini, Martina ; Bazzocchi, Alberto ; Ponti, Federico ; Battista, Giuseppe ; Venturoli, Stefano ; Meriggiola, Maria C.</creatorcontrib><description>Gender dysphoria is characterized by a strong discomfort with the gender assigned at birth and the urge to live as a member of the opposite gender. The acquisition of phenotypic features of the desired gender requires the use of cross‐sex hormones. Female‐to‐male (FtM) transsexual persons are treated with testosterone to induce virilization. The aim of the study was to assess the effects of three different testosterone formulations on body weight and composition and metabolic and bone parameters. Forty‐five FtM transsexuals were randomly assigned to receive testoviron depot (i.m.: 100 mg/10 days; n = 15), testosterone gel (50 mg/die; n = 15), and testosterone undecanoate (i.m.: 1,000 mg every 6 weeks for the first 6 weeks and then every 12 weeks, n = 15). FtM individuals were studied before, at week 30, and at week 54 of testosterone treatment. Anthropometric, metabolic, bone, hematological, and biochemical parameters were evaluated at baseline and after 12 months of treatment. Lean body mass significantly increased and fat mass decreased in all groups. No modifications were reported in fasting insulin and insulin sensitivity index. High‐density plasma lipoprotein levels declined significantly and low‐density lipoprotein concentrations increased significantly in the three groups. The activated partial thromboplastin time and factor I did not change while prothrombin time significantly increased in all groups. At week 54, all subjects were amenorrheic and time to amenorrhea did not differ between the three groups. Current general life satisfaction was increased in all subjects after 1 year of treatment. One‐year testosterone administration in FtM transsexuals appears to be very safe with no differences among the testosterone formulations used. Our study is preliminary, and the detection of subtle or long‐term differences in the effects of the three formulations may require further larger and longer term studies in this and other populations. Pelusi C, Costantino A, Martelli V, Lambertini M, Bazzocchi A, Ponti F, Battista G, Venturoli S, and Meriggiola MC. Effects of three different testosterone formulations in female‐to‐male transsexual persons. J Sex Med 2014;11:3002–3011.</description><identifier>ISSN: 1743-6095</identifier><identifier>EISSN: 1743-6109</identifier><identifier>DOI: 10.1111/jsm.12698</identifier><identifier>PMID: 25250780</identifier><language>eng</language><publisher>Netherlands: Elsevier Inc</publisher><subject>Adult ; Blood Coagulation - drug effects ; Body Composition ; Body Composition - drug effects ; Body Weight - drug effects ; Bone ; Bone Density - drug effects ; Drug Combinations ; Female ; Gels ; Gender Dysphoria ; Gonadal Steroid Hormones - therapeutic use ; Humans ; Insulin - blood ; Life Satisfaction ; Lipid Metabolism - drug effects ; Male ; Patient Satisfaction ; Testosterone ; Testosterone - analogs &amp; derivatives ; Testosterone - therapeutic use ; Transsexualism - drug therapy ; Transsexuals ; Treatment Outcome</subject><ispartof>Journal of sexual medicine, 2014-12, Vol.11 (12), p.3002-3011</ispartof><rights>2014 International Society for Sexual Medicine</rights><rights>2014 International Society for Sexual Medicine.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4358-522e2e8d2d1f21e7c366cde8538aa97abb3dc8e4dcce428eeb065e5a7cff16033</citedby><cites>FETCH-LOGICAL-c4358-522e2e8d2d1f21e7c366cde8538aa97abb3dc8e4dcce428eeb065e5a7cff16033</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjsm.12698$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjsm.12698$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25250780$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pelusi, Carla</creatorcontrib><creatorcontrib>Costantino, Antonietta</creatorcontrib><creatorcontrib>Martelli, Valentina</creatorcontrib><creatorcontrib>Lambertini, Martina</creatorcontrib><creatorcontrib>Bazzocchi, Alberto</creatorcontrib><creatorcontrib>Ponti, Federico</creatorcontrib><creatorcontrib>Battista, Giuseppe</creatorcontrib><creatorcontrib>Venturoli, Stefano</creatorcontrib><creatorcontrib>Meriggiola, Maria C.</creatorcontrib><title>Effects of Three Different Testosterone Formulations in Female‐to‐Male Transsexual Persons</title><title>Journal of sexual medicine</title><addtitle>J Sex Med</addtitle><description>Gender dysphoria is characterized by a strong discomfort with the gender assigned at birth and the urge to live as a member of the opposite gender. The acquisition of phenotypic features of the desired gender requires the use of cross‐sex hormones. Female‐to‐male (FtM) transsexual persons are treated with testosterone to induce virilization. The aim of the study was to assess the effects of three different testosterone formulations on body weight and composition and metabolic and bone parameters. Forty‐five FtM transsexuals were randomly assigned to receive testoviron depot (i.m.: 100 mg/10 days; n = 15), testosterone gel (50 mg/die; n = 15), and testosterone undecanoate (i.m.: 1,000 mg every 6 weeks for the first 6 weeks and then every 12 weeks, n = 15). FtM individuals were studied before, at week 30, and at week 54 of testosterone treatment. Anthropometric, metabolic, bone, hematological, and biochemical parameters were evaluated at baseline and after 12 months of treatment. Lean body mass significantly increased and fat mass decreased in all groups. No modifications were reported in fasting insulin and insulin sensitivity index. High‐density plasma lipoprotein levels declined significantly and low‐density lipoprotein concentrations increased significantly in the three groups. The activated partial thromboplastin time and factor I did not change while prothrombin time significantly increased in all groups. At week 54, all subjects were amenorrheic and time to amenorrhea did not differ between the three groups. Current general life satisfaction was increased in all subjects after 1 year of treatment. One‐year testosterone administration in FtM transsexuals appears to be very safe with no differences among the testosterone formulations used. Our study is preliminary, and the detection of subtle or long‐term differences in the effects of the three formulations may require further larger and longer term studies in this and other populations. Pelusi C, Costantino A, Martelli V, Lambertini M, Bazzocchi A, Ponti F, Battista G, Venturoli S, and Meriggiola MC. Effects of three different testosterone formulations in female‐to‐male transsexual persons. J Sex Med 2014;11:3002–3011.</description><subject>Adult</subject><subject>Blood Coagulation - drug effects</subject><subject>Body Composition</subject><subject>Body Composition - drug effects</subject><subject>Body Weight - drug effects</subject><subject>Bone</subject><subject>Bone Density - drug effects</subject><subject>Drug Combinations</subject><subject>Female</subject><subject>Gels</subject><subject>Gender Dysphoria</subject><subject>Gonadal Steroid Hormones - therapeutic use</subject><subject>Humans</subject><subject>Insulin - blood</subject><subject>Life Satisfaction</subject><subject>Lipid Metabolism - drug effects</subject><subject>Male</subject><subject>Patient Satisfaction</subject><subject>Testosterone</subject><subject>Testosterone - analogs &amp; derivatives</subject><subject>Testosterone - therapeutic use</subject><subject>Transsexualism - drug therapy</subject><subject>Transsexuals</subject><subject>Treatment Outcome</subject><issn>1743-6095</issn><issn>1743-6109</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kUtOwzAQhi0EoqWw4ALIS1ik9aNO0iUqLQ-1AomyxXKdiXCVxMVOgO44AmfkJBjasoJZjEejb37N_EbomJIuDdFb-LJLWTxId1CbJn0exZQMdrc1GYgWOvB-QQgPwfZRiwkmSJKSNnoc5Tno2mOb49mTA8AXJnQcVDWega-tr8HZCvDYurIpVG1s5bGp8BhKVcDn-0dtQ5qGGs-cqryHt0YV-A6cD-Qh2stV4eFo83bQw3g0G15Fk9vL6-H5JNJ9LtJIMAYM0oxlNGcUEs3jWGeQCp4qNUjUfM4znUI_0xr6LAWYk1iAUInOcxqHszrodK27dPa5CXvL0ngNRaEqsI2XNOZhTjBOAnq2RrWz3jvI5dKZUrmVpER-2ymDnfLHzsCebGSbeQnZL7n1LwC9NfBqClj9ryRv7qdbSb6egGDHiwEnvTZQaciMCx8hM2v-WOQLTdqUNQ</recordid><startdate>201412</startdate><enddate>201412</enddate><creator>Pelusi, Carla</creator><creator>Costantino, Antonietta</creator><creator>Martelli, Valentina</creator><creator>Lambertini, Martina</creator><creator>Bazzocchi, Alberto</creator><creator>Ponti, Federico</creator><creator>Battista, Giuseppe</creator><creator>Venturoli, Stefano</creator><creator>Meriggiola, Maria C.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201412</creationdate><title>Effects of Three Different Testosterone Formulations in Female‐to‐Male Transsexual Persons</title><author>Pelusi, Carla ; Costantino, Antonietta ; Martelli, Valentina ; Lambertini, Martina ; Bazzocchi, Alberto ; Ponti, Federico ; Battista, Giuseppe ; Venturoli, Stefano ; Meriggiola, Maria C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4358-522e2e8d2d1f21e7c366cde8538aa97abb3dc8e4dcce428eeb065e5a7cff16033</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Blood Coagulation - drug effects</topic><topic>Body Composition</topic><topic>Body Composition - drug effects</topic><topic>Body Weight - drug effects</topic><topic>Bone</topic><topic>Bone Density - drug effects</topic><topic>Drug Combinations</topic><topic>Female</topic><topic>Gels</topic><topic>Gender Dysphoria</topic><topic>Gonadal Steroid Hormones - therapeutic use</topic><topic>Humans</topic><topic>Insulin - blood</topic><topic>Life Satisfaction</topic><topic>Lipid Metabolism - drug effects</topic><topic>Male</topic><topic>Patient Satisfaction</topic><topic>Testosterone</topic><topic>Testosterone - analogs &amp; derivatives</topic><topic>Testosterone - therapeutic use</topic><topic>Transsexualism - drug therapy</topic><topic>Transsexuals</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pelusi, Carla</creatorcontrib><creatorcontrib>Costantino, Antonietta</creatorcontrib><creatorcontrib>Martelli, Valentina</creatorcontrib><creatorcontrib>Lambertini, Martina</creatorcontrib><creatorcontrib>Bazzocchi, Alberto</creatorcontrib><creatorcontrib>Ponti, Federico</creatorcontrib><creatorcontrib>Battista, Giuseppe</creatorcontrib><creatorcontrib>Venturoli, Stefano</creatorcontrib><creatorcontrib>Meriggiola, Maria C.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of sexual medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pelusi, Carla</au><au>Costantino, Antonietta</au><au>Martelli, Valentina</au><au>Lambertini, Martina</au><au>Bazzocchi, Alberto</au><au>Ponti, Federico</au><au>Battista, Giuseppe</au><au>Venturoli, Stefano</au><au>Meriggiola, Maria C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of Three Different Testosterone Formulations in Female‐to‐Male Transsexual Persons</atitle><jtitle>Journal of sexual medicine</jtitle><addtitle>J Sex Med</addtitle><date>2014-12</date><risdate>2014</risdate><volume>11</volume><issue>12</issue><spage>3002</spage><epage>3011</epage><pages>3002-3011</pages><issn>1743-6095</issn><eissn>1743-6109</eissn><abstract>Gender dysphoria is characterized by a strong discomfort with the gender assigned at birth and the urge to live as a member of the opposite gender. The acquisition of phenotypic features of the desired gender requires the use of cross‐sex hormones. Female‐to‐male (FtM) transsexual persons are treated with testosterone to induce virilization. The aim of the study was to assess the effects of three different testosterone formulations on body weight and composition and metabolic and bone parameters. Forty‐five FtM transsexuals were randomly assigned to receive testoviron depot (i.m.: 100 mg/10 days; n = 15), testosterone gel (50 mg/die; n = 15), and testosterone undecanoate (i.m.: 1,000 mg every 6 weeks for the first 6 weeks and then every 12 weeks, n = 15). FtM individuals were studied before, at week 30, and at week 54 of testosterone treatment. Anthropometric, metabolic, bone, hematological, and biochemical parameters were evaluated at baseline and after 12 months of treatment. Lean body mass significantly increased and fat mass decreased in all groups. No modifications were reported in fasting insulin and insulin sensitivity index. High‐density plasma lipoprotein levels declined significantly and low‐density lipoprotein concentrations increased significantly in the three groups. The activated partial thromboplastin time and factor I did not change while prothrombin time significantly increased in all groups. At week 54, all subjects were amenorrheic and time to amenorrhea did not differ between the three groups. Current general life satisfaction was increased in all subjects after 1 year of treatment. One‐year testosterone administration in FtM transsexuals appears to be very safe with no differences among the testosterone formulations used. Our study is preliminary, and the detection of subtle or long‐term differences in the effects of the three formulations may require further larger and longer term studies in this and other populations. Pelusi C, Costantino A, Martelli V, Lambertini M, Bazzocchi A, Ponti F, Battista G, Venturoli S, and Meriggiola MC. Effects of three different testosterone formulations in female‐to‐male transsexual persons. J Sex Med 2014;11:3002–3011.</abstract><cop>Netherlands</cop><pub>Elsevier Inc</pub><pmid>25250780</pmid><doi>10.1111/jsm.12698</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1743-6095
ispartof Journal of sexual medicine, 2014-12, Vol.11 (12), p.3002-3011
issn 1743-6095
1743-6109
language eng
recordid cdi_proquest_miscellaneous_1634285230
source MEDLINE; Oxford University Press Journals All Titles (1996-Current); Wiley Online Library All Journals
subjects Adult
Blood Coagulation - drug effects
Body Composition
Body Composition - drug effects
Body Weight - drug effects
Bone
Bone Density - drug effects
Drug Combinations
Female
Gels
Gender Dysphoria
Gonadal Steroid Hormones - therapeutic use
Humans
Insulin - blood
Life Satisfaction
Lipid Metabolism - drug effects
Male
Patient Satisfaction
Testosterone
Testosterone - analogs & derivatives
Testosterone - therapeutic use
Transsexualism - drug therapy
Transsexuals
Treatment Outcome
title Effects of Three Different Testosterone Formulations in Female‐to‐Male Transsexual Persons
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T16%3A41%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20Three%20Different%20Testosterone%20Formulations%20in%20Female%E2%80%90to%E2%80%90Male%20Transsexual%20Persons&rft.jtitle=Journal%20of%20sexual%20medicine&rft.au=Pelusi,%20Carla&rft.date=2014-12&rft.volume=11&rft.issue=12&rft.spage=3002&rft.epage=3011&rft.pages=3002-3011&rft.issn=1743-6095&rft.eissn=1743-6109&rft_id=info:doi/10.1111/jsm.12698&rft_dat=%3Cproquest_cross%3E1634285230%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1634285230&rft_id=info:pmid/25250780&rft_els_id=S1743609515306263&rfr_iscdi=true